Study guide

10.2 KEPI Immunization Schedule & Vaccine Logistics

Clinical Officers Council Pre-Internship Examination Kenya

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Overview & Exam Strategy

1.1 About the COC Pre-Internship Examination 1.2 Clinical Decision-Making & Preparation Strategy

2 Chapter 2: Infectious & Communicable Diseases (Internal Medicine)

2.1 Malaria Diagnosis & Case Management 2.2 Tuberculosis & Leprosy Control 2.3 HIV/AIDS & Opportunistic Infections 2.4 Enteric & Neglected Tropical Infections

3 Chapter 3: Cardiovascular & Respiratory Medicine (Internal Medicine)

3.1 Hypertension & Cardiovascular Disorders 3.2 Respiratory Disorders & Acute Emergencies 3.3 Venous Thromboembolism & Vascular Emergencies

4 Chapter 4: Metabolic, Gastrointestinal & Neurological Medicine (Internal Medicine)

4.1 Diabetes Mellitus & Endocrine Emergencies 4.2 Gastrointestinal & Hepatorenal Disorders 4.3 Neurological Emergencies & Acute Toxicology

5 Chapter 5: Trauma Resuscitation & Emergency Surgery (General Surgery)

5.1 ATLS Primary Survey & Trauma Resuscitation 5.2 Burn Assessment & Fluid Resuscitation 5.3 Surgical Wounds, Infections & Tetanus Prophylaxis

6 Chapter 6: Acute Abdomen & Gastrointestinal Surgery (General Surgery)

6.1 Acute Appendicitis & Peritonitis 6.2 Intestinal Obstruction & Abdominal Hernias 6.3 Hepatobiliary, Pancreatic & Anorectal Surgical Conditions

7 Chapter 7: Orthopedics, Urology & Special Surgical Emergencies (General Surgery)

7.1 Fractures, Dislocations & Cast Management 7.2 Acute Compartment Syndrome & Limb Emergencies 7.3 Urological Emergencies & Pelvic Trauma 7.4 Emergency Airway, Anesthesia & Oncology Screening

8 Chapter 8: Essential Newborn Care & Neonatal Conditions (Pediatrics)

8.1 Immediate Newborn Care & Neonatal Resuscitation 8.2 Neonatal Jaundice, Sepsis & Common Disorders 8.3 Low Birth Weight & Kangaroo Mother Care

9 Chapter 9: IMCI Guidelines & Common Pediatric Conditions (Pediatrics)

9.1 IMCI Principles & General Danger Signs 9.2 Cough, Fast Breathing & Pediatric Pneumonia 9.3 Pediatric Diarrheal Diseases & Dehydration 9.4 Acute Pediatric Infections: Meningitis, Croup & Febrile Seizures

10 Chapter 10: Child Nutrition, KEPI & Preventive Pediatrics (Pediatrics)

10.1 Severe Acute Malnutrition (SAM) Management 10.2 KEPI Immunization Schedule & Vaccine Logistics 10.3 Pediatric Prophylaxis & Early Infant Diagnosis

11 Chapter 11: Antenatal Care & Medical Complications of Pregnancy (Obstetrics & Gynecology)

11.1 Focused Antenatal Care & Routine ANC Screening 11.2 Hypertensive Disorders of Pregnancy & Eclampsia 11.3 Medical Disorders & Infections in Pregnancy

12 Chapter 12: Labor, Delivery & Obstetric Emergencies (Obstetrics & Gynecology)

12.1 Normal Labor & Partograph Monitoring 12.2 Active Management of the Third Stage of Labor & PPH 12.3 Antepartum Hemorrhage & Uterine Rupture 12.4 Induction of Labor & Malpresentation Emergencies

13 Chapter 13: Puerperium, Gynecological Disorders & Family Planning (Obstetrics & Gynecology)

13.1 Puerperal Sepsis & Postnatal Complications 13.2 Pelvic Inflammatory Disease & Gynecological Conditions 13.3 Modern Contraceptive Technology & WHO MEC Criteria

14 Chapter 14: Primary Health Care & Devolved Health Systems (Community Health)

14.1 Primary Health Care Principles & Universal Health Coverage 14.2 Kenya Health Service Delivery Structure & Devolved Governance 14.3 Kenya Community Health Strategy & Level 1 Services

15 Chapter 15: Epidemiology, Disease Surveillance & Outbreak Response (Community Health)

15.1 Epidemiological Principles & Health Indicators 15.2 Integrated Disease Surveillance and Response (IDSR) 15.3 Vector Control & Neglected Tropical Diseases

16 Chapter 16: Environmental Health, Waste Management & Cold Chain (Community Health)

16.1 Water Quality & Household Water Treatment 16.2 Community Sanitation & Excreta Disposal 16.3 Healthcare Waste Management & Infection Prevention Control 16.4 Vaccine Cold Chain Management & Quality Monitoring

17 Chapter 17: Health Systems Management — Leadership, Policy & Financing

17.1 Management Functions, Leadership & Supportive Supervision 17.2 Kenya Health Policy, Planning & the Devolved Budget Cycle 17.3 Health Financing & Universal Health Coverage under the Social Health Authority 17.4 Human Resource Management, Scheme of Service & Performance Appraisal

18 Chapter 18: Health Commodities, Information & Quality Management

18.1 Health Commodity & Supply Chain Management (KEMSA) 18.2 Health Information Systems, Records & KHIS Reporting 18.3 Quality Improvement, Clinical Audit & Patient Safety

19 Chapter 19: Professional Practice, Ethics & Medico-Legal Responsibility

19.1 Scope of Practice, Registration, Licensing & Professional Discipline 19.2 Medical Ethics, Informed Consent & Patient Rights 19.3 Medico-Legal Documentation, Statutory Notification & Facility Safety Governance

10.2 KEPI Immunization Schedule & Vaccine Logistics

Key Takeaways Explain This Topic AI

The Kenya routine immunization schedule gives BCG and OPV 0 at birth; Pentavalent (DTP-HepB-Hib), OPV, PCV-10 and ROTAVAC at 6, 10 and 14 weeks; IPV 1 at 14 weeks; Measles-Rubella 1, IPV 2 and yellow fever (endemic counties) at 9 months; and Measles-Rubella 2 at 18 months.

Three changes took effect on 1 November 2025: HPV moved from two doses to a single dose at 10 years, IPV moved from one dose to two (14 weeks and 9 months), and the malaria vaccine transitioned from RTS,S/AS01 to R21/Matrix-M with expanded sub-county coverage.

The malaria vaccine is a 4-dose series at 6, 7, 9 and 24 months given only in designated malaria-endemic sub-counties; the 24-month dose is the one most often missed because it falls outside the routine infant visits.

Specific routes and sites are standardized: BCG intradermally (0.05 mL, right upper arm); Pentavalent, PCV-10, IPV, HPV and malaria vaccine intramuscularly (0.5 mL, anterolateral thigh or deltoid); Measles-Rubella subcutaneously (0.5 mL, right upper arm); OPV and ROTAVAC orally.

Cold chain requires a continuous +2°C to +8°C at facility level, with OPV held at -15°C to -25°C only at central and regional bulk depots; freeze-sensitive vaccines (Pentavalent, PCV-10, Td, HPV, HepB, IPV) must never be frozen, and the Shake Test is the protocol for confirming freeze damage before discarding.

Last updated: September 2026

KEPI Immunization Schedule & Vaccine Logistics

The Kenya Expanded Programme on Immunization (KEPI), coordinated under the National Vaccines and Immunization Program (NVIP) of the Ministry of Health, is one of Kenya's most cost-effective and impactful public health interventions. Immunization protects infants and young children against major infectious killers: tuberculosis, poliomyelitis, diphtheria, pertussis, tetanus, hepatitis B, Haemophilus influenzae type b invasive disease, pneumococcal pneumonia and meningitis, rotavirus enteritis, measles, rubella, yellow fever, and human papillomavirus-associated cervical malignancy.

For the Clinical Officers Council (COC) Pre-Internship Examination, candidates must demonstrate flawless recall of vaccination timetables, precise routes, dosages, and anatomical sites, alongside rigorous knowledge of the cold chain, freeze-damage detection (the Shake Test), and Vaccine Vial Monitor (VVM) interpretation.

1. Complete Kenya Immunization Timetable (Birth to 10 Years)

The table below details the official national schedule administered at Child Welfare Clinics (CWCs) across Kenya:

Age of Child Vaccine Name Target Antigens Included Dose Volume Route Anatomical Site

At Birth (Within 2 weeks) BCG Mycobacterium bovis (attenuated strain) 0.05 mL (0.1 mL if > 1 year) Intradermal (ID) Right upper arm (insertion of deltoid)

At Birth (Within 2 weeks) OPV 0 (Birth Dose) Live attenuated poliovirus types 1 and 3 2 drops Oral Directly into mouth

  • 6 Weeks Pentavalent 1 DTP-HepB-Hib 0.5 mL Intramuscular (IM) Left upper anterolateral thigh
  • OPV 1 Poliovirus types 1 and 3 2 drops Oral Directly into mouth
  • PCV-10 1 10-valent Pneumococcal Conjugate 0.5 mL Intramuscular (IM) Right upper anterolateral thigh
  • ROTAVAC 1 Live attenuated Rotavirus (monovalent 116E) 5 drops Oral Directly into mouth
  • 10 Weeks Pentavalent 2 DTP-HepB-Hib 0.5 mL Intramuscular (IM) Left upper anterolateral thigh
  • OPV 2 Poliovirus types 1 and 3 2 drops Oral Directly into mouth
  • PCV-10 2 10-valent Pneumococcal Conjugate 0.5 mL Intramuscular (IM) Right upper anterolateral thigh
  • ROTAVAC 2 Live attenuated Rotavirus 5 drops Oral Directly into mouth
  • 14 Weeks Pentavalent 3 DTP-HepB-Hib 0.5 mL Intramuscular (IM) Left upper anterolateral thigh
  • OPV 3 Poliovirus types 1 and 3 2 drops Oral Directly into mouth
  • PCV-10 3 10-valent Pneumococcal Conjugate 0.5 mL Intramuscular (IM) Right upper anterolateral thigh
  • ROTAVAC 3 Live attenuated Rotavirus 5 drops Oral Directly into mouth

IPV 1 Inactivated Poliovirus (Types 1, 2, 3) 0.5 mL Intramuscular (IM) Right upper anterolateral thigh (2.5 cm apart from PCV-10)

6 Months Vitamin A Retinol Palmitate 100,000 IU (Blue capsule) Oral Nipple snipped, drops into mouth

Malaria vaccine, dose 1 R21/Matrix-M P. falciparum pre-erythrocytic antigen 0.5 mL Intramuscular (IM) Anterolateral thigh (malaria-endemic sub-counties only)

7 Months Malaria vaccine, dose 2 R21/Matrix-M 0.5 mL Intramuscular (IM) Anterolateral thigh (endemic sub-counties only)

9 Months MR 1 Measles and Rubella (live attenuated) 0.5 mL Subcutaneous (SC) Right upper deltoid

IPV 2 Inactivated Poliovirus (Types 1, 2, 3) 0.5 mL Intramuscular (IM) Anterolateral thigh — added from 1 November 2025

Malaria vaccine, dose 3 R21/Matrix-M 0.5 mL Intramuscular (IM) Anterolateral thigh (endemic sub-counties only)

Yellow Fever 17D live attenuated strain 0.5 mL Subcutaneous (SC) Left upper deltoid (Restricted to high-risk endemic ASAL counties)

12 Months Deworming Albendazole (or Mebendazole 500 mg) 400 mg (200 mg if 12–23m per some protocols) Oral Chewable tablet

  • Vitamin A Retinol Palmitate 200,000 IU (Red capsule) Oral Nipple snipped, drops into mouth
  • 18 Months MR 2 Measles and Rubella (Second Dose) 0.5 mL Subcutaneous (SC) Right upper deltoid

24 Months Malaria vaccine, dose 4 R21/Matrix-M 0.5 mL Intramuscular (IM) Anterolateral thigh (endemic sub-counties only)

10 Years HPV (Adolescent Girls) Human Papillomavirus types 16 and 18 0.5 mL Intramuscular (IM) Left deltoid — single dose from 1 November 2025

Three Schedule Changes That Took Effect on 1 November 2025

Kenya revised the routine schedule in the 2025/2026 financial year. Any revision material, chart booklet, or past paper printed before November 2025 is out of date on these three points, and they are exactly the kind of detail an examiner uses to separate current candidates from those revising off old notes:

  • What changed Before From 1 November 2025
  • HPV 2 doses at 10 years, 6 months apart 1 dose at 10 years
  • IPV 1 dose at 14 weeks 2 doses — 14 weeks and 9 months

Malaria vaccine RTS,S/AS01, subnational pilot geography R21/Matrix-M , expanded to more sub-counties in endemic zones

HPV single dose. WHO's Strategic Advisory Group of Experts concluded that one dose gives equally effective, durable protection against the oncogenic HPV types that cause cervical cancer. Kenya adopted this in November 2025. A single visit doubles the number of girls who can be protected with the same resources and removes the second-visit cost that drove most of the previous drop-off.

IPV second dose (IPV 2) at 9 months. Added in line with WHO and Global Polio Eradication Initiative recommendations to strengthen type-2 humoral immunity as part of the polio endgame strategy. Note the practical consequence at the 9-month visit: the child now receives MR 1, IPV 2, yellow fever where applicable, and malaria dose 3 in endemic sub-counties. Use separate syringes and sites, and space injections at least 2.5 cm apart in the same limb.

Malaria vaccine. Kenya was one of three Malaria Vaccine Implementation Programme pilot countries and introduced RTS,S/AS01 in 2019 in selected western sub-counties. From November 2025 the programme transitioned to the R21/Matrix-M formulation and expanded geographically. The schedule is a 4-dose series at 6, 7, 9 and 24 months , delivered only in designated malaria-endemic sub-counties — it is not a national-schedule vaccine, and dose 4 at 24 months is the dose most commonly missed because it falls outside the routine infant visits.

  • 2. Technical Administration Guidelines & Clinical Nuances
  • BCG (Bacille Calmette-Guérin)

Dilution & Storage: Reconstituted with supplied physiological saline diluent. Must be protected from direct sunlight (photolabile) and used within 6 hours of reconstitution.

Injection Technique: Administered strictly intradermally on the right upper arm at the insertion of the deltoid , using a 26G or 27G short-bevel needle held bevel-up at a 10° to 15° angle to the skin. Correct administration produces a pale, blanched, pitted intradermal wheal measuring 5 to 8 mm ('orange-peel' appearance).

Normal BCG Evolution:

Immediate: Transient wheal that flattens within 30 minutes.

2 to 3 weeks: Indurated, erythematous papule develops at injection site.

5 to 6 weeks: Papule softens, ulcerates, and discharges serous fluid.

8 to 12 weeks: Ulcer spontaneously dries and forms a crust, leaving a permanent, flat or slightly depressed BCG scar measuring 3 to 7 mm.

Clinical Pitfalls: Subcutaneous administration causes deep abscesses and suppurative regional axillary lymphadenitis (BCG-oma). Do not apply ointments, antibiotics, or bandages over the normal BCG lesion; counsel mother to leave it uncovered.

OPV vs. IPV Polio Eradication Strategy

OPV (Bivalent Oral Poliovirus Vaccine): Contains attenuated type 1 and type 3 polioviruses. Secretes secretory IgA on the intestinal mucosa, preventing wild virus replication and gut shedding. It is delivered as 2 drops directly onto the child's tongue.

OPV 0 (Birth Dose): Must be given within the first 14 days of life . If an infant presents after 14 days without OPV 0, do not give OPV 0; start directly with OPV 1 at 6 weeks.

IPV (Inactivated Poliovirus Vaccine): Kenya now gives two doses — IPV 1 at 14 weeks and IPV 2 at 9 months , each 0.5 mL IM — following the schedule change of 1 November 2025. IPV contains inactivated types 1, 2, and 3 virus. Because type 2 was withdrawn from OPV to eliminate Vaccine-Associated Paralytic Poliomyelitis (VAPP) and circulating Vaccine-Derived Polioviruses (cVDPV), IPV provides the systemic humoral immunity against type 2 poliovirus that bivalent OPV cannot. The second dose was added because one dose leaves a measurable proportion of children seronegative to type 2.

Rotavirus Vaccine (ROTAVAC)

Kenya utilizes the live attenuated monovalent 116E strain (ROTAVAC), administered as 5 drops orally at 6, 10, and 14 weeks . If an infant spits out the drops immediately, re-administer the dose once gently.

Measles-Rubella (MR 1 and MR 2)

Given at 9 months (MR 1) and 18 months (MR 2) to address primary vaccine failure (approximately 10–15% of infants fail to seroconvert at 9 months due to lingering maternal transplacental antibodies). Administered subcutaneously into the right upper deltoid at a 45° angle using a 25G needle.

Malaria Vaccine (R21/Matrix-M)

Who gets it: infants in designated malaria-endemic sub-counties only, concentrated in the lake-endemic and coastal-endemic zones. A child born in Nairobi or Turkana does not receive it on the routine schedule; a child in Homa Bay or Busia does.

Schedule: 4 doses at 6, 7, 9 and 24 months , 0.5 mL IM into the anterolateral thigh.

Why it starts at 6 months and not 6 weeks: efficacy in the 6–12-week co-administration age group was too low to justify infant-schedule delivery, so the series was designed to begin around 5–6 months.

Counselling point: the vaccine reduces but does not abolish malaria risk. Insecticide-treated nets, indoor residual spraying, intermittent preventive treatment in pregnancy, and prompt testing and treatment all continue unchanged. Parents who believe a vaccinated child cannot get malaria present late with severe disease.

HPV Vaccine

Single dose at 10 years for girls, from 1 November 2025 (previously 2 doses 6 months apart).

Protects against the oncogenic HPV types responsible for the majority of cervical cancer, which remains a leading cancer killer of Kenyan women.

Given intramuscularly into the deltoid. It is freeze-sensitive — never let it freeze.

Yellow Fever Endemic Counties in Kenya

Yellow fever vaccination is not universally administered across all 47 counties; it is routinely given at 9 months in designated high-risk counties along the Rift Valley and Lake Victoria basin: Baringo, Elgeyo Marakwet, West Pokot, Turkana, Kisumu, and Kericho .

3. Vaccine Cold Chain Logistics

The cold chain is the continuous, temperature-controlled supply chain system that ensures vaccines maintain their biochemical potency and immunological efficacy from the point of manufacture to the point of administration. COLD CHAIN TEMPERATURE ZONES

  • Temperature Level Vaccine Types Stored
  • ─────────────────────────────────────────────────────────────────────────────
  • 15°C to -25°C • OPV (At National & Regional Bulk Depots)
  • (Deep Freeze)
  • ─────────────────────────────────────────────────────────────────────────────
  • +2°C to +8°C • ALL VACCINES at Health Center / Dispensary level
  • (Standard Refrigerator Target) • Pentavalent, PCV-10, Td, HPV, HepB
  • BCG, MR, Yellow Fever, ROTAVAC, IPV
  • ─────────────────────────────────────────────────────────────────────────────
  • > +8°C • Cold chain breach: High risk of heat inactivation

< +2°C • Freezing breach: Destroys aluminum-adsorbed vaccines!

Facility Refrigerator Management

Target Temperature: Maintained strictly between +2.0°C and +8.0°C .

Temperature Monitoring: Read twice daily (morning at 08:00 and evening at 16:00, including weekends and public holidays) using a calibrated 30-day electronic temperature logger (Fridge-tag 2) or alcohol thermometer mounted in the middle shelf. Recorded on a standardized MOH 335 Temperature Chart.

Storage Layout Rules:

Top Shelf / Freezer Compartment: Ice packs for conditioning; OPV may be frozen only at bulk depots.

Upper / Middle Shelves (+2°C to +4°C): Heat-sensitive, freeze-tolerant live viral vaccines (OPV, Measles-Rubella, BCG, Yellow Fever).

Lower Shelves (+4°C to +8°C): Freeze-sensitive, aluminum-adsorbed vaccines (Pentavalent, PCV-10, Td, HPV, HepB, IPV).

Bottom Shelf / Crisper: Filled with chilled bottles of water to stabilize interior temperature during power outages. Never place vaccines in the door compartments or bottom crisper.

  • 4. Freeze Sensitivity & The Shake Test Protocol
  • Freeze-Sensitive vs. Freeze-Tolerant Vaccines FREEZE-SENSITIVE VACCINES FREEZE-TOLERANT VACCINES
  • (NEVER ALLOW TO FREEZE!) (Can withstand freezing)
  • ─────────────────────────────── ──────────────────────────────
  • Pentavalent (DTP-HepB-Hib) • OPV (Oral Poliovirus)
  • PCV-10 (Pneumococcal) • BCG (Freeze-dried)
  • Td / TT (Tetanus Toxoid) • Measles-Rubella (Lyophilized)
  • HPV (Human Papillomavirus) • Yellow Fever (Lyophilized)
  • Hepatitis B
  • IPV (Inactivated Polio)

Pathophysiology of Freeze Damage: Vaccines containing aluminum adjuvants (aluminum hydroxide or aluminum phosphate) form a delicate colloidal suspension. If frozen below 0°C, ice crystals crush the aluminum lattice, irreversibly breaking the bond between the adjuvant and the microbial antigen. The adjuvant forms heavy, insoluble granules that fall out of suspension, permanently destroying vaccine immunogenicity and markedly increasing the risk of sterile subcutaneous abscesses.

The Shake Test Step-by-Step Protocol

When a refrigerator breaches < 0°C or freeze-indicators (Freeze-tag / Freeze-check) trigger, the clinician must conduct the Shake Test before discarding suspected vials: SHAKE TEST WORKFLOW:

[Step 1: PREPARE CONTROL VIAL]

  • Take a vial of the identical vaccine from the same manufacturer and lot number.
  • Deliberately freeze it solid at -20°C for 24 hours, then thaw completely at room temperature.
  • Clearly mark it: "FROZEN CONTROL".
  • │
  • ▼
  • [Step 2: SELECT TEST VIAL]
  • Take the suspected vial from the compromised refrigerator.
  • │
  • ▼
  • [Step 3: SHAKE TOGETHER]
  • Hold both vials in one hand and shake vigorously for 10 to 15 seconds.
  • │
  • ▼
  • [Step 4: OBSERVE SEDIMENTATION]
  • Place both vials side by side on a flat, well-lit surface.
  • Observe settling behavior at 5, 15, and 30 minutes.
  • │
  • ▼
  • [Step 5: INTERPRETATION]

• TEST VIAL SETTLES SLOWLY (Remains cloudy much longer than control):

► PASSED: Vaccine was NOT freeze-damaged -> Safe to use.

• TEST VIAL SETTLES RAPIDLY (Sediments and clears at same rate or faster than control):

► FAILED: Vaccine WAS frozen and damaged -> DISCARD IMMEDIATELY.

  • 5. Vaccine Vial Monitor (VVM) & Multi-Dose Vial Policy
  • Vaccine Vial Monitor (VVM) Stages

The VVM is a temperature-sensitive label comprising an inner white square surrounded by an outer purple reference circle. It reflects cumulative heat exposure over time.

VVM Stage Visual Appearance of Inner Square Meaning & Action Required

Stage 1 Inner square is noticeably lighter than outer circle Vaccine has received negligible heat exposure; USABLE .

Stage 2 Inner square has darkened slightly , but remains distinctly lighter than outer circle Vaccine has experienced moderate heat exposure but remains potent; USABLE (prioritize for use before Stage 1 vials).

Stage 3 Inner square matches the color of the outer circle ( DISCARD THRESHOLD ) Vaccine has reached its heat threshold and lost potency; DO NOT USE - DISCARD IMMEDIATELY .

Stage 4 Inner square is noticeably darker than outer circle Vaccine has suffered severe heat exposure; DO NOT USE - DISCARD IMMEDIATELY .

Exam Key: Even if the manufacturer's calendar expiration date stamped on the vial has not passed, a vial with a VVM at Stage 3 or Stage 4 must be destroyed immediately .

Multi-Dose Vial Policy (MDVP)

The Kenya NVIP distinguishes between opened multi-dose vials of liquid injectable vaccines versus reconstituted lyophilized vaccines:

Reconstituted Freeze-Dried Vaccines (BCG, Measles-Rubella, Yellow Fever):

Strict Rule: Must be DISCARDED within 6 hours of reconstitution or at the end of the immunization session, whichever comes first.

Rationale: These vaccines contain no antimicrobial preservatives. Unused reconstituted vials are prone to Staphylococcus aureus colonization, which can cause fatal pediatric Toxic Shock Syndrome (TSS) .

Liquid Injectable Vaccines (Pentavalent, PCV-10, OPV, Td, IPV):

Opened vials may be retained and used for up to 28 days , provided that:

The expiration date has not passed.

Stored continuously between +2°C and +8°C.

The VVM has not reached Stage 3 or 4.

The vial septum was not submerged in water and strict aseptic technique was maintained.